<link rel="stylesheet" href="styles.f3b1fba60ec7970c.css">

Publication:
The Prognostic Impact of HER2 Status and Survival Outcomes in Metastatic Triple Negative Breast Cancer

Loading...
Thumbnail Image

Departments

Item type:Organizational Unit,

School / College / Institute

Item type:Organizational Unit,
SCHOOL OF MEDICINE
Upper Org Unit

Program

Organization Authors

Co-Authors

Turkel, Alper

Baydar, Ece

Colak, Rumeysa

Ozturk, Ahmet Emin

Sakalar, Teoman

Akbas, Sinem

Gur, Hasibe Bilge

Cavdar, Eyyup

Yilmaz, Mesut

Cabuk, Devrim

Date

Language

Embargo Status

No

Journal Title

Journal ISSN

Volume Title

Alternative Title

Abstract

Background/Aim: This study investigated the prognostic impact of human epidermal growth factor-2 receptor (HER2) status on the survival of patients with metastatic triple-negative breast cancer (TNBC). Patients and Methods: This multicenter, retrospective study included 168 patients diagnosed with recurrent or de novo metastatic TNBC between April 2013 and September 2024. Patients were categorized into two groups: HER2- negative (n=121, 72%) and HER2-low (n=47, 28%). Clinicopathological features and survival outcomes were compared between groups. Results: The median follow-up was 44 months [95% confidence interval (CI)=35.7-52.2]. All patients received systemic chemotherapy as part of their first-line treatment. The median progression-free survival (PFS) in all patients was 9 months (95%CI=7.7-10.3 months). The median overall survival (OS) in all patients was 22 months (95%CI=17.4-26.5 months). Higher Ki67 value at diagnosis was a significant poor prognostic factor for median OS (29 months vs. 15 months, p <0.001). HER2-negative patients had significantly worse median OS than HER2-low patients (19 months vs. 33 months, p =0.026). In multivariate analysis, the HER2-low group had significantly longer median OS than the HER2-negative group [hazard ratio=0.64 (95%CI=0.42-0.98), p =0.040]. Conclusion: HER2-low expression was associated with significantly improved survival compared with HER2-negative status in metastatic TNBC. These findings highlight HER2 status as a potential prognostic factor, particularly relevant in settings with limited access to novel therapies such as immunotherapy or antibody-drug conjugates.

Source

Publisher

International Institute of Anticancer Research

Citation

item.page.haspartof

Source

In Vivo

item.page.ispartofseries

item.page.edition

DOI

10.21873/invivo.14160

item.page.datauri

item.page.link

Rights

CC BY-NC-ND (Attribution-NonCommercial-NoDerivs)

Copyrights Note

Creative Commons license

Except where otherwise noted, this item's license is described as CC BY-NC-ND (Attribution-NonCommercial-NoDerivs)

Endorsement

Review

Supplemented By

Referenced By

Related Patent

Related Goal

Google Scholar
Scholar'da Ara ↗
Altmetric
Dimensions
PlumX Metrikleri
BIP! Indicators